Filling and Emptying Cystometries ("Backwards Cystometry"): a Feasibility and Validation Study

Filling and Emptying Cystometries: a Feasibility and Validation Study in Order to Simplify the Manometric Follow-up of Overactive Detrusor in Neurological Patients Under Anticholinergic or Botulinum Toxin Injections.

This study evaluate the feasibility and the accuracy of an emptying cystometry in order to simplify the manometric follow-up of overactive detrusor in neurological patients under anticholinergic or botulinum toxin injections.

Study Overview

• Status: Completed
• Conditions: Lower Urinary Tract Symptoms
• Intervention / Treatment: Other: Pressure measurement

Detailed Description

Bladder pressure assessment is necessary for the diagnosis, the prognostic assessment and the management of neurogenic bladder. High bladder pressures increase the rate of urological complications and mortality in patients with neurogenic bladder. Thus many treatments are proposed in order to improve bladder compliance and reduce uninhibited detrusor contractions (anticholinergic drugs, botulinum toxin injections, cystoplasty, sacral neuromodulation, beta-3-agonist, posterior tibial nerve stimulation).

Clinical data, symptoms scales, quality of life questionnaires, renal ultrasound, biological tests of renal function and urodynamic studies are used to control the treatment efficacy of neurogenic lower urinary tract dysfunction. Filling cystometry is the usual way to record bladder pressure. Urodynamic techniques using external pressure transducers (microtip, air-filled or fluid-perfused catheters) connected to the patient with fluid-filled lines are recommended. This multichannel cystometry is performed in a specialized department with the inconvenience of delays for appointments and cost of the urodynamic assessment. Moreover, only some parameters are important and are taken in account in the follow-up of these neurogenic bladders: bladder capacity, bladder compliance and maximum detrusor pressure at the end of the filling phase. All these parameters can be recorded with a self-assessment of bladder pressure at home with a very simple device made of 1) a self-intermittent catheter; 2) a three way stopcock; 3) a simple graduated tube. This device has in fact been used in the past to realize cystometries, in particular in the elderly subject. A such device should provide a monitoring in changes in bladder pressure in order to initiate adjustments in treatment sooner than would be achieved when patients are evaluated periodically but less frequently in the neurourology department. The early detection of high bladder pressures may avoid bladder deformation, reflux and upper tract deterioration. Moreover, the home control of appropriate bladder pressure may improve the patients' quality of live by reducing the constraint linked to the time-consuming specialized follow-up.

In this study, the investigators will test a reverse single channel cystometry performed just after a classical filling cystometry during the usual emptying by means of a device allowing serial bladder pressure measurements during the bladder emptying. In case of such a feasibility and a good precision of the reverse cystometry, the manometric follow-up of overactive detrusor in neurological patients under anticholinergic or botulinum toxin injections could be simplified.

The aim of this study is to assess the feasibility and the accuracy of sequential measurements of bladder pressure during the bladder emptying and to compare the evolution of bladder pressures during the emptying phase with the bladder pressures recorded during the filling phase.

Patients over 18 years old, consulting for lower urinary tract symptoms and performing an urodynamic examination with a cystometry in a tertiary center are included.

History, treatment and urodynamics data are recorded. Conventional supine multichannel cystometry with isotonic saline infused at 50ml/min (filling cystometry), conform to the International Continence Society (ICS) recommendations will be performed. At the end of the standard cystometry when the maximum cystometric capacity will be reached, if no micturition was obtained, urodynamic catheter was withdrawn and a CH12 urinary catheter will be introduced in the bladder according to the usual department procedure (usually, this catheter allows to empty the bladder). This catheter will be connected to a three-way stopcock. The second way of the stopcock will permit the emptying into a measuring container, graduated each 50ml. The third way of the stopcock will be connected via a tube extension to a rigid vertical 70cm tube (central venous pressure set) graduated each centimeter. The zero pressure of the vertical tube will be set at the upper edge of the symphysis pubis. For measuring the bladder pressure at the maximum cystometric capacity, the valve will be open between the bladder and the graduated tube, manometric data will be derived by observing the rise of the column of fluid in the centimeter scale tube. This procedure will be repeated every 50ml until bladder full emptying.

The investigators will compared each bladder pressure measures every 50ml during the "backwards cystometry" with each bladder pressure measured every 50ml from the maximum capacity during the filling cystometry.

Primary outcome is the agreement between the two cystometries evaluated using a kappa coefficient.

Secondary outcome is the correlation between the pressures during the two cystometries.

• Study Type: Observational
• Enrollment (Actual): 11

Contacts and Locations

Study Locations

• France
  • Paris, France, 75020
    • Department of Neuro-urology, Tenon hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients consulting for an urodynamic assessment in a tertiary center in neuro-urology

Description

Inclusion Criteria:

• Follow in neuro-urology for lower urinary tract symptoms
• Appointment for urodynamic assessment

Exclusion Criteria:

• detrusor overactivity
• micturition during or at the end of the filling cystometry

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patients enrolled; Patients over 18 years old, consulting for lower urinary tract symptoms and performing an urodynamic examination with a cystometry in a tertiary center are included. First pressure measurement in the bladder during the classic cystometry. Second measurement of bladder pressures during the bladder emptying.	Other: Pressure measurement; Observational study No intervention, only fragmenting the emptying of the bladder

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Agreement	Agreement between the two cystometries evaluated using a kappa coefficient.	1 Day : during the urodynamic assessment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation	Correlation between the pressures during the two cystometries.	1 Day : during the urodynamic assessment

Collaborators and Investigators

• Sponsor: Pierre and Marie Curie University

Study record dates

Study Major Dates

• Study Start (ACTUAL): July 31, 2017
• Primary Completion (ACTUAL): August 28, 2017
• Study Completion (ACTUAL): September 29, 2017

Study Registration Dates

• First Submitted: August 16, 2017
• First Submitted That Met QC Criteria: August 16, 2017
• First Posted (ACTUAL): August 21, 2017

Study Record Updates

• Last Update Posted (ACTUAL): September 25, 2019
• Last Update Submitted That Met QC Criteria: September 24, 2019
• Last Verified: September 1, 2019

More Information

Terms related to this study

• Keywords: follow-up; urodynamic; backwards cystometry; reverse cystometry
• Additional Relevant MeSH Terms: Urological Manifestations; Lower Urinary Tract Symptoms
• Other Study ID Numbers: P GREEN 01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No